Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Vitiligo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Vitiligo. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-003473-42 Sponsor Protocol Number: 14086 Start Date*: 2016-06-16
    Sponsor Name:University of Nottingham
    Full Title: Home Interventions and Light therapy for the treatment of vitiligo
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    17.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-019994-13 Sponsor Protocol Number: RD.03.SPR.40117E Start Date*: 2010-09-21
    Sponsor Name:GALDERMA R&D
    Full Title: EXPLORATORY STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CD07387 SOLUTION IN PATIENTS WITH VITILIGO
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047642 Vitiligo LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000361-32 Sponsor Protocol Number: INCB18424-214 Start Date*: 2021-07-21
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo (TRuE-V MOA)
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-001442-35 Sponsor Protocol Number: PTZ Start Date*: 2021-06-04
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: A PHASE 2 MONOCENTRIC PILOT STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PIOGLITAZONE IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO
    Medical condition: NON SEGMENTAL VITILIGO WITH BSA BETWEEN 2% AND 50% AND A NON-SATISFACTORY RESPONSE (LESS THAN 10%) TO A PREVIOUS PHOTOTHERAPY CYCLE
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10047643 Vitiligo vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017425-19 Sponsor Protocol Number: AGO/2009/012 Start Date*: 2009-12-24
    Sponsor Name:University Hospital Ghent
    Full Title: Vitiligo en het Koebnerfenomeen. (Vitiligo inductie- en therapie model : klinische en immunologische analyse)
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-017757-36 Sponsor Protocol Number: LEA/VIT Start Date*: 2010-11-23
    Sponsor Name:Instituto Científico y Tecnológico de Navarra
    Full Title: Ensayo clínico fase I-II, controlado intraindividualmente para evaluar la eficacia del trasplante de melanocitos autólogos en monocapa sobre un soporte de membrana amniótica en el tratamiento del v...
    Medical condition: piebaldismo, vitíligo metamérico, vitíligo focal o vitíligo generalizado que lleven al menos 1 año de estabilidad sin despigmentación ni repigmentación espontánea o tras tratamiento médico habitual
    Disease: Version SOC Term Classification Code Term Level
    12.1 10047642 Vitiligo LLT
    12.1 10047643 Vitiligo vulgaris LLT
    12.1 10047642 Vitiligo PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000081-15 Sponsor Protocol Number: M19-051 Start Date*: 2021-08-24
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose- Ranging Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Non-Segmental Vitiligo
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2015-003552-48 Sponsor Protocol Number: AGO/2015/009 Start Date*: 2016-03-22
    Sponsor Name:Ghent University Hospital
    Full Title: Pilot trial to determine the efficacy of secukinumab in active non-segmental vitiligo
    Medical condition: Vitiligo
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000847-28 Sponsor Protocol Number: INCB18424-307 Start Date*: 2020-05-05
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) PL (Completed) BG (Completed) ES (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-000987-53 Sponsor Protocol Number: INCB18424-308 Start Date*: 2021-04-18
    Sponsor Name:Incyte Corporation
    Full Title: A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000846-37 Sponsor Protocol Number: INCB18424-306 Start Date*: 2020-05-19
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) PL (Completed) DE (Completed) BG (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001271-20 Sponsor Protocol Number: B7981019 Start Date*: 2019-07-30
    Sponsor Name:Pfizer Inc 235 East 42nd Street, New York, NY10017 US
    Full Title: A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVAL...
    Medical condition: Vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-002003-37 Sponsor Protocol Number: CHUBX2022/03 Start Date*: 2023-03-22
    Sponsor Name:Centre Hospitalier Universitaire de Bordeaux
    Full Title: Efficacy and tolerance of the association of ANIFROLUMAB (300mg) IV every four weeks and phototherapy versus phototherapy in adults with progressive vitiligo: a randomized double blind prospective,...
    Medical condition: non-segmental (symmetrical) vitiligo with a body surface area involved >5% excluding hands and feet
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004536-29 Sponsor Protocol Number: CHUBX2017/44 Start Date*: 2022-12-29
    Sponsor Name:CHU de Bordeaux
    Full Title: Efficacy and tolerance of the association of MTX and phototherapy versus phototherapy in adults with progressive vitiligo : a randomized double blind prospective study (METVI)
    Medical condition: Progressive vitiligo
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10047642 Vitiligo PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-000838-12 Sponsor Protocol Number: Vit-Caps-Protocol-V1.0 Start Date*: 2006-08-03
    Sponsor Name:Peter Wolf MD, Department of Dermatology, Medical University of Graz
    Full Title: Die Bedeutung des sensorischen Nervensystems für die Repigmentierung der Haut bei Vitiligo (engl.: The role of the sensory nervous system for repigmentation in vitiligo)
    Medical condition: Vitiligo
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2008-006903-22 Sponsor Protocol Number: SNIP1 Start Date*: 2009-07-29
    Sponsor Name:Academic Medical Center
    Full Title: Narrow band UV-B phototherapy and fluticasone proprionate versus narrow band UV-B phototherapy and placebo for the treatment of active vitiligo: a randomized double blind controlled trial
    Medical condition: Narrow band ultra violet B phototherapy is the gold standard for the treatment of vitiligo vulgaris. Ultra violet A and fluticasone proprionate (cutivate) together have shown significant better rep...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005079-12 Sponsor Protocol Number: CHUBX2019/21 Start Date*: 2021-03-24
    Sponsor Name:Centre Hospitalier Universitaire de Bordeaux
    Full Title: Efficacy and tolerance of the association of baricitinib (4mg) and phototherapy versus phototherapy in adults with progressive vitiligo: a randomized double blind, non comparative phase II study.
    Medical condition: progressive vitiligo
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000169-10 Sponsor Protocol Number: CUV101 Start Date*: 2011-04-08
    Sponsor Name:CLINUVEL PHARMACUETICALS LTD.
    Full Title: A Phase II, Randomised Pilot Study to Evaluate the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegm...
    Medical condition: Subjects affected by non-segmental vitiligo
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10062080 Pigmentation disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002922-79 Sponsor Protocol Number: Vitiligo Start Date*: 2006-06-12
    Sponsor Name:Avemedica, s.r.o.
    Full Title: Investigation of 0.1% tacrolimus ointment for the treatment of vitiligo patients
    Medical condition: Kožní onemocnění vitiligo
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-003215-22 Sponsor Protocol Number: vit-001 Start Date*: 2005-02-04
    Sponsor Name:Antonio Noda Cabrera
    Full Title: Ensayo clínico piloto, unicéntrico, aleatorizado, doble ciego, con dos grupos paralelos sobre el efecto del Tacalcitol en pacientes afectos de vitíligo.
    Medical condition: vitiligo vulgaris
    Disease: Version SOC Term Classification Code Term Level
    5.0 10040829 NEC
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 29 08:58:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA